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ABSTRACT 
Objective: 
Accurate and early detection of sepsis poses a significant challenge in burn 
populations. Our objective was to assess whether Procalcitonin (PCT) is a marker of 
blood culture positive sepsis in moderate to severe paediatric burns. 
Methods: 
We analysed PCT in 27 children admitted with burns of 15-65% Total Body Surface 
Area. PCT was measured at admission (baseline), 24, and 48 hours post-admission 
and during periods of suspected sepsis (diagnosed against pre-defined criteria). 
Patients were categorised into controls with no episodes of suspected sepsis (n = 10) 
and those with episodes of suspected sepsis (SS, n = 17). The latter were split into 
two groups based on blood culture results: culture positive (bacteraemia) and culture 
negative patients.  
Results: 
Baseline PCT increased with burn size (OR [95%CI]: 1.15 [1.02-1.29]). SS patients 
had larger burns than controls (median 31% vs. 20%; p=0.003). Only 5/23 suspected 
sepsis episodes were blood culture-positive. PCT levels were similar in culture positive 
and culture negative patients (p = 0.43). Sensitivity for predicting positive blood culture 
was 100% (95%CI: 47.8-100.0%) but specificity was only 22.2% (95%CI: 6.4-47.6%). 
Area under the curve was poor at 0.62 (95%CI: 0.33-0.90). There was no significant 
change in PCT from baseline to septic episode in either group (positive: p=0.35; 
negative: p=0.95).  
Conclusions: 
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We conclude that evidence for the use of PCT to diagnose bacteraemia in this 
population is poor with burn size playing a significant role implying a correlation with 
inflammation rather than sepsis.  
 
Keywords: Procalcitonin; sepsis; burn injury; children; C-reactive protein 
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INTRODUCTION 
Sepsis is an important cause of morbidity and mortality in burn patients and requires 
prompt treatment with appropriate antibiotics.1-3 The prevalence of sepsis in burns 
patients varies from 8 – 43%.4 However, the likely development of a Systemic 
Inflammatory Response Syndrome (SIRS) in patients with burns of more than 20% 
Total Body Surface Area (TBSA), means that criteria usually relied upon for the early 
identification of sepsis complicate decision-making about the diagnosis.5 Definitive 
diagnosis of sepsis in burns patients still relies upon non-specific serum markers and 
the retrospective analysis of blood cultures which take at least 48 hours to obtain and 
are unavailable when decisions on antibiotic use must be made. A proportion of 
burned patients will therefore be considered to have sepsis and undergo broad-
spectrum antibiotic treatment, when in fact their abnormal markers are a result of a 
systemic inflammatory process in the absence of sepsis. This results in overuse of 
antibiotics, increasing bacterial resistance within individuals (and in the wider 
community) and may compromise the response to treatment if true sepsis does 
subsequently develop.6,7 A rapid and accurate method of identifying sepsis on which 
treatment decisions can be based is therefore required. 
Procalcitonin (PCT), a precursor to the hormone calcitonin, has long been 
controversially discussed as a more specific marker of sepsis that might provide a way 
of identifying infection before blood culture results are available.8-24 In general, PCT 
levels are very low in uninfected patients but can increase markedly within a few hours 
of sepsis onset.25 The utility of PCT in diagnosis and decision-making regarding 
antibiotic therapy has already been well investigated in a variety of disease entities, 
including respiratory tract infections, and in the critically ill.8-13 In respiratory tract 
infections, there is now evidence that use of PCT improves diagnosis and leads to 
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reduced antibiotic use with no evidence that this approach increases the risk of 
mortality.10 A particular characteristic of PCT is that it has been shown to be helpful in 
distinguishing bacterial infections from viral infections and SIRS.26 As most patients 
with severe burns will develop SIRS, it is this characteristic that has resulted in PCT 
being considered as a potential marker of sepsis in the adult burns population.15-18,20-
23,27 Very few studies have investigated its use in paediatric burns.28,29 
The aim of this study is to assess whether PCT is a specific marker for sepsis or 
whether it simply reflects the development of SIRS in moderate to severe paediatric 
burn patients. We specifically investigate: (1) the pattern of PCT levels during the first 
2-3 days post admission (baseline) when wound infection and sepsis are likely to be 
absent, (2) whether PCT levels during a suspected sepsis episode differ in those 
patients whose blood cultures come back negative and those that come back positive 
(proven bacteraemia) from blood samples taken during a suspected sepsis episode, 
and (3) whether the change in PCT levels from baseline to that during a suspected 
sepsis episode could be a useful predictor of proven bacteraemia. We also look at the 
relationship between PCT and burn size. As C-reactive protein (CRP) is also a 
commonly used marker of acute inflammatory response and infection, we compared 
its performance to predict proven bacteraemia against PCT.  
 
METHODS  
This study was a prospective multicentre cohort study carried out in three UK 
hospitals: Bristol Children’s Burns Centre, Alder Hey Children’s Hospital, Liverpool and 
the Royal Manchester Children’s Hospital. The inclusion criteria were children of less 
than 16 years of age admitted to the study hospitals with scalds of more than or equal 
 6 
 
to 20% Total Body Surface Area (TBSA) or flame burns greater than or equal to 15% 
TBSA. The consent of all study participants and/or their parents was obtained before 
enrolment within the study. The study was designed such that participation would have 
no bearing on standard clinical management and to ensure there was no need for 
additional procedures. Ethical approval was obtained from the South West Research 
Ethics Committee. Patients were recruited between April 2009 and October 2013. 
A Sampling 
Blood samples were taken at three separate time points (0, 24, and 48 hrs) after 
admission as per routine clinical practice (baseline). Following this initial period, blood 
samples were only collected for patients showing clinical signs of possible sepsis 
(suspected sepsis). Suspected sepsis was defined using objective criteria which were 
comprised of both clinical and biochemical parameters that are routinely available to 
clinicians. The clinical aspect of the criteria was based on the American Burn 
Association definition of sepsis in burns.30 The criteria applied are shown in Table 1. 
Suspected sepsis episodes separated by >24 hours were treated as independent 
episodes. At times of suspected sepsis, routine physiological observations and blood 
tests including White Blood Cell estimation, C-reactive protein and blood cultures were 
undertaken as per normal practice. A small volume of the blood samples was kept for 
PCT analysis. These were separated on receipt in the laboratory and frozen 
immediately at -80 degrees C (stored up to 13 months) until analysis. Samples were 
thawed at room temperature and mixed before analysis. The procalcitonin assay was 
performed using the Elecsys BRAHMS PCT assay (available from Roche, West 
Sussex, UK) on a Roche Cobas e602 immunoassay analyser (Roche, West Sussex, 
UK). We used two cut-offs for plasma PCT levels to assess diagnostic accuracy, ≥0.5 
ng/mL and >2 ng/mL. Values below 0.5 ng/mL are considered normal and therefore 
 7 
 
bacterial sepsis is unlikely. With PCT levels between 0.5 and 2 ng/mL, a systemic 
infection cannot be excluded and levels above 2 ng/mL represent an increased 
likelihood of bacterial sepsis being present.25 Management of the suspected septic 
episode, including antibiotic administration, was in line with standard hospital care. 
‘Proven bacteraemia’ was defined as an episode where the patient showed clinical 
signs of sepsis and had a confirmed positive blood culture. The PCT results were not 
available during the study period. CRP was measured using an immunoturbidimetric 
assay on the Roche Cobas analysers. CRP values ≤10mg/L were considered 
normal.26  
 
Table 1. ABA (American Burns Association) criteria for the suspicion of sepsis. The 
presence of three or more components were required for any episode to be considered 
as suspected sepsis.  
Criteria for the suspicion of sepsis 
• Temperature >38.9°C or <36.5°C for >2hrs 
• Failure to absorb feed if previously absorbing 
• WBC <4.0x109/L or >15x109/L 
• Platelet count <100x109/L 
• INR >1.5 
• CRP > 10 mg/L 
• Hyperglycaemia (>11mM/L) in the absence of pre-existing diabetes 
• Progressive tachycardia or tachypnoea (>2 standard deviations above 
age-specific norms) 
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A Statistical analyses 
All statistical analyses were conducted in STATA v. 14.31 All descriptive demographic 
analyses were performed using non-parametric tests (Mann-Whitney U-tests, Chi-
square tests, Kendall’s rank correlation). Differences in PCT (ng/mL) baseline levels 
at 0, 24, and 48 hours post-admission were analysed across time points using 
Friedman repeated measures tests. Logistic regressions with resulting odds ratios and 
95% confidence intervals were used to assess associations between both baseline 
PCT levels and septic episode PCT levels and TBSA, age, gender and burn type. 
Diagnostic accuracy measures such as sensitivity, specificity, positive likelihood ratios 
(LR+), negative likelihood ratios (LR-), positive predictive values (PPV) and negative 
predictive values (NPV) were calculated for predicting positive blood culture results 
(i.e. proven bacteraemia) using two binary cut-offs of PCT levels (≥0.5 mg/mL 
[moderate/high risk] and >2 mg/mL [high risk]). Area under the curve (AUC) was 
established using Receiver Operating Curve (ROC) analysis using PCT as a 
continuous variable. All CRP analyses were conducted in the same way. 
 
RESULTS 
A Patient demographics 
A total of 29 patients were recruited to the study across the three hospital sites. Two 
patients were excluded from the analyses; one patient was erroneously enrolled and 
the data for the second patient was incomplete due to a suspected error in PCT 
measurement with inadequate remaining sample for re-analysis. One of the sites 
recruited significantly more girls than boys compared to the other sites (χ2 = 7.25, p = 
0.03) but there was no difference in age (χ2 = 0.32, p = 0.85), burn type (χ2 = 2.56, p 
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= 0.28) or % TBSA (χ2 = 0.62, p = 0.73) seen at the different sites. All patients were 
pooled for analyses.  
 
Of the 27 patients included, there was an equal distribution between male (n=13) and 
female (n=14) and between scalds (n=13) and flame burns (n=14). Median age of all 
patients was 39 months (Interquartile range [IQR]: 23-75). Median burn size was 27% 
TBSA (IQR 20-34). There was no difference in % TBSA between burn types (z=0.80, 
p=0.42).  
 
A PCT levels during baseline 
The timing of the blood samples taken varied around the three established time points 
(0, 24, and 48 hrs), but was never later than 60 hrs post admission (range 0 – 60hrs; 
mean [SD]: 29hrs [17]). Although for some individuals, PCT levels fluctuated over the 
first few days (Figure 1), repeated measures analysis showed no statistical difference 
across the three separate time points (p = 0.22).  We therefore used the first baseline 
time point at which blood samples were taken (mean [SD] hrs after admission: 11 [8]) 
as a measure of baseline PCT levels. Using both the 0.5 ng/mL and 2 ng/mL cut-offs, 
logistic regressions showed that larger burns were more likely to exhibit PCT levels 
above the two cut-offs (≥0.5: OR [95% CI]: 1.15 [1.00 – 1.31]; >2: OR [95% CI]: 1.15 
[1.02 – 1.29]). There was no association with either age (≥0.5: OR [95% CI]: 0.99 [0.97 
– 1.01]; >2: OR [95% CI]: 0.98 [0.96 – 1.01]) or gender (≥0.5: OR [95% CI]: 4.27 [0.80 
– 22.93]; >2: OR [95% CI]: 0.64 [0.14 – 3.04]). 
  
[INSERT FIGURE 1] 
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A Using PCT to predict proven bacteraemia 
Seventeen patients (63%) met the criteria for suspected sepsis at least once during 
their admission (range 1-4 episodes per patient). All multiple episodes were 
considered independent data points as there were >24 hrs in between them. In total 
23 suspected sepsis episodes were recorded. The number of days post admission at 
which patients displayed first signs of suspected sepsis varied between 3 and 33 days 
(median [IQR] = 8 [4-13]). Only five out of the 23 (22%) episodes (five different 
patients) were classed as blood culture positive (proven bacteraemia) based on the 
sample taken during each episode. The remaining 18 episodes all had negative blood 
cultures. Although the 17 patients who developed signs of sepsis had larger burns 
than those remaining 10 who did not develop any signs during their hospital stay 
(median [IQR] % TBSA, suspected sepsis: 31 [27-40]; controls: 20 [19.5-22]; z = 2.94, 
p = 0.003), TBSA was not different between culture positive and culture negative 
patients (median [IQR] % TBSA, positive: 33.5 [32-47]; negative: 28 [25-47]; z = -1.10, 
p = 0.27).  
 
Looking at the continuous values of PCT during a suspected sepsis episode, median 
levels at the time of a septic episode were no different to those that were later 
confirmed positive on blood culture (median [IQR]: 4.05 [1.22 – 14.48]) compared to 
those confirmed as negative (1.28 [0.72 – 8.99]; z = 078, p = 0.43). Using the standard 
0.5 ng/mL cut-off, only 4/23 (17%) patients with episodes of suspected sepsis had 
PCT levels considered normal. Using the 0.5 cut-off, sensitivity for predicting a positive 
blood culture result was 100% (95% CI: 47.8-100.0%) but specificity only 22.2% (95% 
CI: 6.4-47.6%; table 2). Using the higher cut-off of >2 ng/mL which is highly suggestive 
of a septic process, sensitivity was reduced to 60.0% (95% CI: 14.7-94.7%) but 
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specificity increased to 55.6% (95% CI: 30.8-78.5%; table 2). The ROC analysis 
suggests that a cut-off of 4 ng/mL would provide the optimum sensitivity and specificity 
without compromising one or the other, but values are still relatively low at 60% vs. 
67%. AUC for predicting positive blood culture was poor at 0.62 (95% CI: 0.33 – 0.90).  
 
Table 2. Contingency table of PCT levels during suspected sepsis episodes to predict 
positive blood culture (proven bacteraemia) using two different risk cut-offs: 
moderate/high risk ≥0.5 ng/mL (a), and high risk >2 ng/mL (b). LR+ = Positive 
Likelihood Ratio, LR- = Negative Likelihood Ratio, PPV = Positive Predictive Value, 
NPV = Negative Predictive Value, CI = Confidence Interval.  
 
 
 
 
(a) PCT levels Blood-positive (N) Blood-negative (N) Total (N) 
Moderate/High (≥0.5) 5 14 19 
Low (<0.5) 0 4 4 
Total 5 18 23 
    
    
Sensitivity (%, 95% CI) 100.0 (47.8 – 100.0) 
22.2 (6.4 – 47.6) 
1.3 (1.0 – 1.7) 
Not quantifiable 
26.3 (21.8 – 31.4) 
100.0 (39.8 – 100.0) 
Specificity (%, 95% CI) 
LR+ (95% CI) 
LR- (95% CI) 
PPV (%, 95% CI) 
NPV (%, 95% CI) 
    
(b) PCT levels Blood-positive (N) Blood-negative (N) Total (N) 
High (>2) 3 8 11 
Low/moderate (≤2) 2 10 12 
Total 5 18 23 
    
Sensitivity (%, 95% CI) 60.0 (14.7 – 94.7) 
55.6 (30.8 – 78.5) 
1.4 (0. 6 – 3.3) 
0.7 (0.2 – 2.3) 
27.3 (13.4 – 47.6) 
83.3 (61.3 – 94.1) 
Specificity (%, 95% CI) 
LR+ (95% CI) 
LR- (95% CI) 
PPV (%, 95% CI) 
NPV (%, 95% CI) 
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A Change from baseline to septic episode 
When comparing the change in PCT levels from that shown at baseline to that shown 
during a suspected episode each patient was used as its own control using Wilcoxon 
matched pairs tests (first episode used for those with multiple episodes: n=17). Median 
PCT concentration at admission was 2.09 (IQR: 0.42-4.00) and 1.22 (IQR: 0.72-7.06) 
during septic episodes. There was no change in concentration from baseline to septic 
episode in either the culture negative group (z = -0.06, p = 0.95) or the culture positive 
group (z = -0.94, p = 0.35). Figure 2 shows the changes for all individuals with negative 
and/or positive episodes.  
 
[INSERT FIGURE 2] 
 
A CRP levels 
There was no difference in CRP measured for those patients with positive blood 
culture (median [IQR]: 84.6 [39.9 – 246]) to those who had negative cultures at the 
time of the septic episodes (median [IQR]: 100 [28.2 – 184]; p = 0.51). Only 1 patient 
had CRP levels below the normal cut-off of 10 mg/L. Therefore, sensitivity reached 
100% but specificity was very low at 5.6% (table 3). AUC for proven bacteraemia was 
0.60 (95% CI: 0.29 – 0.91), not significantly different (p = 0.95) from that using PCT. 
There was also no correlation between CRP levels and PCT levels during episodes of 
suspected sepsis (Kendall’s tau-a: 0.08, p = 0.63). 
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Table 3. Contingency table of CRP levels during suspected sepsis episodes to predict 
positive blood culture (proven bacteraemia) using a cut-off of 10 mg/L. LR+ = Positive 
Likelihood Ratio, LR- = Negative Likelihood Ratio, PPV = Positive Predictive Value, 
NPV = Negative Predictive Value, CI = Confidence Interval.  
 
 
 
DISCUSSION 
We found that baseline PCT levels were related to burn size with larger area burns 
displaying higher levels of PCT within 24 hours of admission. Patients who developed 
signs of suspected sepsis during their hospital stay also had larger area burns 
compared to those who did not have any suspected sepsis episodes, suggesting that 
burn size may contribute to the development of systemic inflammatory episodes and 
raised PCT. We found that PCT levels measured during the suspected sepsis 
episodes were of limited use to predict proven bacteraemia. As all patients with 
positive cultures showed PCT levels indicating either moderate or high risk of infection, 
sensitivity was high. However, specificity for ruling infection out was very low as levels 
were elevated in most patients. We also saw no difference between culture negative 
and culture positive patients in terms of the change in PCT levels from baseline to that 
CRP levels Blood-positive (N) Blood-negative (N) Total (N) 
High (≥10) 5 17 22 
Low (<10) 0 1 1 
Total 5 18 23 
    
Sensitivity (%, 95% CI) 100.0 (47.8 – 100.0) 
5.6 (0.1 – 27.3) 
1.1 (0.9 – 1.2) 
Not quantifiable 
22.7 (7.8 – 45.4) 
100.0 (2.5 – 100.0) 
Specificity (%, 95% CI) 
LR+ (95% CI) 
LR- (95% CI) 
PPV (%, 95% CI) 
NPV (%, 95% CI) 
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during septic episodes. CRP levels also showed poor predictive value in our 
population, as all but one episode had values above normal.  
There are some limitations with our study. As this was a small scale preliminary 
study, the main limitation is the low statistical power due to small sample size and low 
prevalence of blood positive patients. The small sample size spread across three 
different centres may have introduced variability in the data as different interpretations 
of clinical signs may be present. However, there is no reason why this variability should 
be different between blood positive and blood negative patients. It is possible that 
freezing and storing the PCT samples for varying lengths of time before analysis could 
affect our results. However, Meisner et al. have shown that PCT shows a great stability 
under different conditions of storage; no differences in concentrations were found 
between samples stored at different temperatures and the percentage decay was 
similar for high and low PCT concentrations. Also, repeated freezing and thawing had 
no effect on PCT concentrations.32 
Several studies have been carried out in burns populations investigating the 
utility of PCT as a predictor of sepsis. However, results are conflicting and inconsistent. 
A systematic review by Mann et al. in 2011 considered the available evidence in adult 
critically ill patients (both burned and non-burned) and concluded that PCT may be a 
promising adjunct to clinical management but varying definitions of sepsis amongst 
the included studies, most of them observational, rendered conclusive findings 
difficult.19 Similarly, a recent meta-analysis and a subsequent retrospective study from 
the same authors examining the use of PCT as a marker for sepsis showed positive 
results with a strong diagnostic ability to discriminate between septic and non-septic 
burn patients.22,23 Again however, studies included in the meta-analyses showed large 
heterogeneity as they varied in how PCT was measured in the lab, in cut-offs used 
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and sample size was generally low giving rise to doubt about its utility as a reliable 
biomarker.  
 
Despite a multitude of studies conducted, very few have been conducted in 
paediatric burn populations. One study addressing use of PCT in paediatric burns 
assessed PCT levels in 20 children with the aim of determining whether a rise in PCT 
could identify times at which the treating surgeon clinically diagnosed sepsis. The 
authors found that PCT was less sensitive than CRP and/or platelet count.28 The study 
was limited by small sample size and using subjective surgeon decisions of sepsis as 
their gold standard. A study published in 2015 assessed both CRP and PCT as 
biomarkers for septic episodes in 48 paediatric burn patients.29 This study, in line with 
ours, found that both PCT and CRP levels were high in majority of patients, regardless 
of infection status. Although this patient group had larger area burns than ours, 
possibly explaining their much higher rate of confirmed infection (67% vs. 22%), their 
results were similar. PCT had a 90% sensitivity but only 19% specificity in predicting 
proven infection, making its clinical utility questionable. Although failure to diagnose 
infection, and potentially serious outcomes as a result, is unlikely, an inability to rule 
out infection can lead to over-prescription of antibiotics with the associated problems 
this brings. It is entirely possible that PCT in paediatric populations is predicting no 
more than a SIRS response, especially as we found that TBSA seems to influence not 
only baseline PCT levels but also those patients who developed suspected sepsis had 
larger % TBSA burns and it is expected they would be more likely to develop SIRS. 
Several studies have shown that severe trauma such as burns can cause elevation of 
PCT and CRP levels in the absence of sepsis.18,25,29 CRP concentration was also part 
of the diagnosis of suspected sepsis in our study so would be naturally high in these 
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patients. However, at the time of bloods being taken during an episode, the absence 
or presence of infection was unknown to us, so a comparison of CRP levels between 
culture positive and negative episodes is still valid. 
Although we used the standard PCT level cut-off of <0.5 ng/mL which in SIRS 
patients means a systemic bacterial infection can be excluded,25 studies have shown 
that other cut-offs may be more useful in predicting infection.33 We did also use a cut-
off of > 2.0 ng/mL, suggesting a systemic infectious process is highly likely,25 but 
despite the specificity increasing using this cut-off, predictive accuracy was still 
relatively poor and AUC using the two different cut-offs were no different. The ROC 
analysis suggested that a cut-off of 4 ng/mL would provide the optimal sensitivity and 
specificity without the expense of one or the other, but confidence intervals are too 
wide to accurately confirm this.  
 
The use of PCT in the diagnosis and monitoring of sepsis has recently been the 
subject of a National Institute for Health and Care Excellence (NICE) Diagnostics 
Assessment Programme published in October 2015 
(https://www.nice.org.uk/guidance/dg18). This programme evaluated whether PCT 
testing in children and in adults presenting with suspected bacterial infection either to 
the emergency department or in an intensive care setting represents clinically- and 
cost-effective use of NHS resources. The decision from NICE currently, is that there 
is insufficient evidence to support the routine adoption of procalcitonin tests in the 
NHS.  
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CONCLUSION 
Given the low incidence of blood culture positive individuals in our study, it is difficult 
to draw any firm conclusions regarding the use of PCT as a biomarker for sepsis in 
this type of paediatric populations. We agree with Cabral et al.’s recent proposal,22 
that to better evaluate the utility of PCT as a biomarker for sepsis in burns, PCT levels 
should be determined frequently, particularly in burn patients with a high risk of 
infection (for example those with larger TBSA), and a large sample size should be 
used. A larger study using more frequent timepoints would also have more power to 
usefully examine whether the combination of baseline PCT and measurement during 
any episode of suspected sepsis would be more useful than a single time-point 
measurement. It would also be crucial to review the importance of different cut-off 
values, methods used to quantify PCT levels and whether combining PCT with several 
other biomarkers is a more useful way to predict a septic process in these patients. 
The effect of burn size and perhaps also response to antibiotics is something that 
needs further exploration. Considering the NICE guidance suggesting there is 
insufficient evidence to support regular testing in the NHS, the time is therefore ripe 
for a multi-centre trial of the utility of PCT testing in children with burns, taking all the 
above factors into account.  
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FIGURE TEXTS 
Figure 1. PCT values over the first two days post-admission for all 27 individuals included in the 
study. Time point 1 = 0 hrs, time point 2 = 24 hrs, time point 3 = 48hrs.  
 
Figure 2. The change in PCT levels from baseline to septic episodes (blood culture negative and 
positive) for the 17 individuals who developed signs of sepsis. Some individuals had multiple 
episodes.  
 
 
